Melbourne, July 16, 2008 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that the United States Patent and Trade Mark Office (USPTO) has granted a key patent, US Patent 7,399,632, through to at least the year 2019.
In conjunction with the company's composition-of-matter patent granted in 2006, US Patent 7,122,178, this new patent delivers a major commercial advantage to both Mesoblast and its United States-based sister company, Angioblast Systems Inc., ensuring that only these companies can commercialise the unique adult stem cells, termed Mesenchymal Precursor Cells (MPC), in the United States, the world's largest market for regenerative medicines.
The granting of the latest patent confers further certainty and significantly increases the commercial value of the adult stem cell platform technology.
The MPC were first identified at the Hanson Institute in Adelaide, Australia, and can repair and regenerate a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.
This new granted patent provides long-term protection for the company's platform technology through broad claims over methods of purifying, isolating, and enriching the company's unique adult stem cells.
Building upon and continuing to expand a broad-based international patent portfolio is fundamental to the commercial strategies of both Mesoblast and Angioblast. This second granted US patent is a major asset for both companies in product commercialisation and establishing strategic business partnerships with global pharmaceutical and medical device companies.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
| ||
|
